Search
Showing results for "early life"
Skin infection burden in remote Aboriginal communities can be reduced by the See, Treat, Prevent (SToP skin sores and scabies) trial
The Skin Health Situational Analysis was conducted in 2017 with and for stakeholders in the Kimberley region as a precursor to the SToP Trial to highlight all that was already known prior to commencement in 2018. It was completed to be a resource for communities in the Kimberley who would like to de
The Ear and Hearing Health team's vision is all children start primary school with good hearing.
Staphylococcus aureus is a common cause of bacteremia, yet the epidemiology and predictors of poor outcome remain inadequately defined in childhood. ISAIAH (Invasive Staphylococcus aureus Infections and Hospitalizations in children) is a prospective, cross-sectional study of S. aureus bacteremia in children hospitalized in Australia and New Zealand over 24 months.
Summarising the current knowledge of Strep A transmission to humans will address gaps in the evidence and inform prevention and control strategies. The objective of this study is to evaluate the modes of transmission and attack rates of group A streptococcal infection in human populations.
ARC is a global network of collaborators committed to reducing the burden of RHD in our lifetime.
The aim of this project is to conduct a situational analysis of the skin health services and activities currently available for managing skin infections within the Kimberley.
In this study we will use new methods to comprehensively test immune responses in blood samples from people with ARF (diagnosed using the Jones Criteria) and healthy volunteers at Royal Darwin and from Auckland Hospital, New Zealand, to find any unique signature that reliably identifies ARF.
STopping Acute Rheumatic Fever Infections to Strengthen Health (STARFISH) brings together a diverse and multidisciplinary research team to investigate the most effective environmental health initiatives (EHIs) aimed at reducing Strep A infections and prevent Acute Rheumatic Fever (ARF).
Since 1955, the recommended strategy for rheumatic heart disease secondary prophylaxis has been benzathine penicillin G injections administered intramuscularly every 4 weeks. Due to dosing frequency, pain, and programmatic challenges, adherence is suboptimal. It has previously been demonstrated that BPG delivered subcutaneously at a standard dose is safe and tolerable and has favorable pharmacokinetics, setting the scene for improved regimens with less frequent administration.